Clinical Significance Of Serum Mrgprx2 As A New Biomarker In Allergic Asthma

Background: Although several biomarkers have been proposed for allergic asthma, parameters are still controversial as biomarkers to reflect the efficacy of treatment. Mas-related G protein-coupled receptor-X2 (MRGPRX2) is a newly emerging agent in allergic and inflammatory disease. Objective: The aim of this study was to analyze the MRGPRX2 concentrations in asthmatic patients, evaluating its role as a predictor of outcomes in allergic asthma. Methods: We enrolled 102 healthy controls (CON), 164 allergic (AL), and 78 nonallergic asthmatic (NA) patients from the Cohort for Reality and Evolution of adult Asthma in Korea (COREA). We measured MRGPRX2 concentration (ng/ml) using an Enzyme-linked immunosorbent assay(ELISA) kit. Results: The mean serum MRGPRX2 level in the allergic asthma was higher than nonallergic and healthy groups (AL: 102.4 ± 54.5 vs. NA: 79.8 ± 52.5 vs. CON: 12.9 ± 9.8, p Conclusion: Allergic asthmatic patients with MRGPRX2 levels≥100 ng/ml had good response of ICS although they need higher dose of ICS to treatment. This is the first study demonstrating the role of MRGPRX2 as new biomarker to predict treatment dose and response of ICS in allergic asthmatic patients.